Please login to the form below

Not currently logged in
Email:
Password:

enasidenib

This page shows the latest enasidenib news and features for those working in and with pharma, biotech and healthcare.

Novartis gets EU nod for leukaemia drug Rydapt

Novartis gets EU nod for leukaemia drug Rydapt

or AML with myelodysplasia-related changes (AML-MRC) – while Celgene/Agios claimed approval for Idhifa (enasidenib) as a treatment for AML patients with the IDH2 mutation.

Latest news

  • Celgene, Agios get FDA OK for leukaemia drug Idhifa Celgene, Agios get FDA OK for leukaemia drug Idhifa

    Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer

  • Celgene bags US priority review for cancer metabolism drug Celgene bags US priority review for cancer metabolism drug

    Celgene bags US priority review for cancer metabolism drug. First approval for enasidenib could be just six months away. ... Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute myeloid

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics